NO20024235L - 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer - Google Patents

5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer

Info

Publication number
NO20024235L
NO20024235L NO20024235A NO20024235A NO20024235L NO 20024235 L NO20024235 L NO 20024235L NO 20024235 A NO20024235 A NO 20024235A NO 20024235 A NO20024235 A NO 20024235A NO 20024235 L NO20024235 L NO 20024235L
Authority
NO
Norway
Prior art keywords
alkylpyrido
tyrosine kinase
kinase inhibitors
pyrimidine
pyrimidine tyrosine
Prior art date
Application number
NO20024235A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024235D0 (no
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20024235D0 publication Critical patent/NO20024235D0/no
Publication of NO20024235L publication Critical patent/NO20024235L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20024235A 2000-03-06 2002-09-05 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer NO20024235L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (fr) 2000-03-06 2001-01-29 Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido[2,3-d]pyrimidines

Publications (2)

Publication Number Publication Date
NO20024235D0 NO20024235D0 (no) 2002-09-05
NO20024235L true NO20024235L (no) 2002-11-05

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024235A NO20024235L (no) 2000-03-06 2002-09-05 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer

Country Status (37)

Country Link
EP (1) EP1268476A1 (fr)
JP (1) JP2003528101A (fr)
KR (1) KR20020075805A (fr)
CN (1) CN1422268A (fr)
AP (1) AP2002002643A0 (fr)
AR (1) AR034119A1 (fr)
AU (1) AU2001233028A1 (fr)
BG (1) BG107161A (fr)
BR (1) BR0109056A (fr)
CA (1) CA2401368A1 (fr)
CO (1) CO5280200A1 (fr)
CR (1) CR6736A (fr)
CZ (1) CZ20022929A3 (fr)
DZ (1) DZ3308A1 (fr)
EA (1) EA200200802A1 (fr)
EE (1) EE200200506A (fr)
GT (1) GT200100037A (fr)
HN (1) HN2001000040A (fr)
HR (1) HRP20020798A2 (fr)
HU (1) HUP0300136A2 (fr)
IL (1) IL151480A0 (fr)
IS (1) IS6524A (fr)
MA (1) MA26881A1 (fr)
MX (1) MXPA02008535A (fr)
NO (1) NO20024235L (fr)
NZ (1) NZ520962A (fr)
OA (1) OA12227A (fr)
PA (1) PA8513201A1 (fr)
PE (1) PE20011177A1 (fr)
PL (1) PL358271A1 (fr)
PY (1) PY0104899A (fr)
SK (1) SK12472002A3 (fr)
SV (1) SV2001000338A (fr)
TN (1) TNSN01036A1 (fr)
WO (1) WO2001070741A1 (fr)
YU (1) YU66502A (fr)
ZA (1) ZA200207110B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE521353T1 (de) 2000-10-23 2011-09-15 Glaxosmithkline Llc Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
DE60206363T2 (de) * 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
MXPA03007623A (es) * 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
WO2003000011A2 (fr) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Nouvelles pyridopyrimidines et leur utilisation
EP1408985A4 (fr) * 2001-06-21 2006-03-22 Ariad Pharma Inc Nouveaux pyridopyrimidones et leurs utilisations
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
AU2003273675A1 (en) 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
EP1590341B1 (fr) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ATE412650T1 (de) * 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
EP1663204B1 (fr) * 2003-08-29 2014-05-07 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
WO2005047284A1 (fr) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Pyrido-7-pyrimidin-7-ones substitues hydroxyalkyle
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
CA2575804A1 (fr) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones utilisees en tant qu'inhibiteurs des plk (polo-like-kinases)
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1865959A2 (fr) 2005-03-25 2007-12-19 Glaxo Group Limited Procede de preparation de derives pyridoý2,3-d¨pyrimidin-7-one et 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one
WO2006110298A2 (fr) 2005-03-25 2006-10-19 Glaxo Group Limited Nouveaux composes
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
CN101395155A (zh) * 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
DK2074122T5 (da) 2006-09-15 2014-03-17 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
EP1914234A1 (fr) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2137184B1 (fr) * 2007-04-03 2013-05-08 Array Biopharma, Inc. Composés imidazo[1,2-a]pyridine utilisés comme inhibiteurs des récepteurs à activité tyrosine kinase
ES2608940T3 (es) * 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
EP2185559A1 (fr) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Forme cristalline d'un dérivé de dihydroptéridione
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
CA2710039C (fr) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarnazones et composes associes, et methodes de traitement du cancer
EP2100894A1 (fr) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
EP2318406B1 (fr) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Composés inhibiteurs et procédés de traitement du cancer
WO2010039740A1 (fr) 2008-09-30 2010-04-08 Exelixis, Inc. Inhibiteurs de pyridopyrimidinone de la pi3 kinase α et de la mtor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2013507395A (ja) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
CA2999435A1 (fr) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Composes et methodes pour le traitement du vih
CA2807498C (fr) * 2010-08-05 2017-02-07 Temple University-Of The Commonwealth System Of Higher Education 8-alkyl-7-oxo-7, 8dihydropyrido[2,3-d]pyrimidine-6-carbonitriles substitues en 2 et leurs utilisations
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
EA025496B1 (ru) * 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
SI2958916T1 (sl) * 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
KR20170032244A (ko) 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
WO2019161224A1 (fr) 2018-02-15 2019-08-22 GiraFpharma LLC Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
CN113166148B (zh) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
AU2022234998B2 (en) * 2021-03-08 2025-04-10 Jinan University Pyridopyrimidine compounds and applications thereof
CN116456987A (zh) * 2021-06-09 2023-07-18 郑州同源康医药有限公司 用作cdk激酶抑制剂的化合物及其应用
JP2025531320A (ja) * 2022-09-16 2025-09-19 イースト チャイナ ノーマル ユニバーシティ Ｒｓｋ阻害剤としてのピリドノピリミジン誘導体及びその応用
WO2024099403A1 (fr) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Composé thioéther ayant une propriété de médicament doux et son utilisation, composition pharmaceutique et utilisation associées
WO2024107730A1 (fr) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Méthodes et compositions pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ES2301194T3 (es) * 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
AU763839B2 (en) * 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
SK12472002A3 (sk) 2003-04-01
PY0104899A (es) 2003-11-03
EA200200802A1 (ru) 2003-02-27
PE20011177A1 (es) 2001-11-23
MA26881A1 (fr) 2004-12-20
WO2001070741A1 (fr) 2001-09-27
CR6736A (es) 2004-03-10
SV2001000338A (es) 2001-11-30
EP1268476A1 (fr) 2003-01-02
EE200200506A (et) 2004-02-16
CO5280200A1 (es) 2003-05-30
NO20024235D0 (no) 2002-09-05
AU2001233028A1 (en) 2001-10-03
MXPA02008535A (es) 2002-12-13
YU66502A (sh) 2005-09-19
TNSN01036A1 (en) 2005-11-10
AP2002002643A0 (en) 2002-12-31
AR034119A1 (es) 2004-02-04
PL358271A1 (pl) 2004-08-09
HUP0300136A2 (en) 2003-05-28
PA8513201A1 (es) 2003-06-30
GT200100037A (es) 2002-03-04
HN2001000040A (es) 2001-09-06
DZ3308A1 (fr) 2001-09-27
CZ20022929A3 (cs) 2003-02-12
IS6524A (is) 2002-08-23
JP2003528101A (ja) 2003-09-24
NZ520962A (en) 2003-09-26
BG107161A (bg) 2003-06-30
OA12227A (en) 2004-03-18
HRP20020798A2 (en) 2004-02-29
CA2401368A1 (fr) 2001-09-27
BR0109056A (pt) 2003-06-03
KR20020075805A (ko) 2002-10-05
CN1422268A (zh) 2003-06-04
ZA200207110B (en) 2003-12-04
IL151480A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
NO20024235D0 (no) 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer
ATE257157T1 (de) Pyrrolo(2,3-d)pyrimidin-verbindungen als protein kinasen hemmer
ATE286045T1 (de) Tyrosin kinaseinhibitoren
IS6968A (is) Nýir týrósínkínasa tálmar
EP1161433A4 (fr) Inhibiteurs de tyrosine kinase
ATE388713T1 (de) 4-amino-6-phenyl-pyrrolo(2,3-d)pyrimidin derivate
NO20031852L (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO20034929D0 (no) 4-amino-5-fenyl-7-cyklobutylpyrrol(2,3-D)pyrimidinderivater
PT1200435E (pt) Derivados de purina inibidores tirosina proteina quinase syk
DZ3266A1 (fr) Pyrido[2,3-d]pyrimidine-2,7-diamine inhibiteurs de kinase
AU2002348394A1 (en) Tyrosine kinase inhibitors
EP1259236A4 (fr) Inhibiteurs de tyrosine-kinase
ATE231866T1 (de) Pyrazolo(4, 3-d)pyrimidine
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
ATE276260T1 (de) 2-aminoalkyl-thieno(2,3-d)pyrimidine
ATE297927T1 (de) Substituierte 3,4-dihydro-pyrido(1,2-a)pyrimidine
DK1226136T3 (da) Tyrosinkinaseinhibitor
AU2002327619A1 (en) Tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors
AU2002337972A1 (en) Tyrosine kinase inhibitors
AU2002326758A1 (en) Tyrosine kinase inhibitors
AU2002326466A1 (en) Tyrosine kinase inhibitors
AU2002304001A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application